Arcutis Biotherapeutics, Inc. (ARQT) Balance Sheet

The sequential increase in total assets and equity, coupled with a decline in total liabilities from $270.4M to $268.0M, suggests the balance sheet is strengthening as revenue scales. The reduction in accumulated deficit from -$1.2B to -$1.1B indicates that profitability is beginning to offset historical losses, a trend that may continue if operating leverage persists. However, the modest cash balance of $34.1M remains a constraint, implying that the strengthening is still fragile and dependent on sustained revenue growth.

The dramatic increase in debt, likely from a convertible or term loan, provides necessary capital but introduces refinancing risk, especially given the company's history of volatile cash flows. The D/E ratio of 0.52, while not extreme, is a significant departure from the near-zero leverage in Q4 2025, suggesting management is prioritizing growth over balance sheet conservatism. Investors should monitor the terms of this debt, as interest expense could pressure margins if revenue growth decelerates.

The negligible PP&E relative to total assets confirms that Arcutis relies on contract manufacturing and outsourced production, consistent with its high gross margins. Goodwill, though slightly declining, is small and unlikely to pose a material impairment risk. The asset mix is dominated by current assets, primarily receivables and inventory, which aligns with a commercial-stage pharma model where working capital efficiency is critical.

The increase in equity, despite no new share issuance in the quarter, suggests that retained earnings are finally contributing positively, a reversal from prior periods of heavy dilution. However, the accumulated deficit of -$1.1B remains substantial, and stock-based compensation continues to dilute shareholders, as noted in the cash flow analysis. The equity base is still thin relative to the company's market cap, implying that future capital raises could further dilute existing holders.

While the current ratio of 2.92 indicates sufficient short-term assets to cover liabilities, the absolute cash balance is low relative to the company's burn rate, even with recent profitability. The cash position of $34.1M, combined with positive operating cash flow of $12.6M in Q2 2026, suggests a runway of roughly 2-3 quarters if losses resume. This thin buffer may necessitate a capital raise, which could be dilutive, especially if market conditions deteriorate.